DOCSLIB.ORG

Price Master for OCHA File

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Price Master for OCHA File Item Code Item Description Item Price 1210000001 FS-SIXTH SEMI-PRIVATE 2365 1210000006 MED/SUR OVERFLOW SEMI-PVT 2365 1210000007 ED OVERFLOW SEMI-PRIV BED 2365 1210000008 SAME DAY ADMIT SEMI-PRIV BED 2365 1210000009 GS-SEVENTH SEMI-PRIV 1BED 2365 1210000010 ICU-MED/SUR SEMI-PRIV BED 2365 1220000001 OB SEMI-PRIVATE 2420 1230000001 G3 PEDIATRICS SEMI PRIVATE 2150 1240000001 PSYCHIATRIC SEMI PRIVATE 2090 1240000002 ED HOLD PSYCH SEMI PRIVATE 2090 1240000003 SBHU SEMI PRIVATE 2090 1260000001 PSYCH DETOX SEMI PRIVATE 2200 1260000002 ED HOLD PSYCH DETOX SEMI PRIV 2200 1700000002 NURSERY ROOM RATE 1650 2000000001 ICU OVERFLOW PACU 3630 2000000002 INTENSIVE CARE 3630 2060000001 FS ISOLATION 2365 2060000002 FS TELEMETRY BED 2365 2060000003 FS TELEMETRY/ISOLATION 2365 2060000005 GS ISOLATION 2365 2060000006 GS TELEMETRY 2365 2060000007 GS TELEMETRY/ISOLATION 2365 2060000008 ICU ISOLATION 2365 2060000009 ED ISOLATION 2365 2060000010 ED TELEMETRY BED 2365 2060000011 ED TELEMETRY/ISOLATION 2150 2500000001 SODIUM CHLORIDE 0.9% RESP 3 ML NEBULIZATION SOLUTION 1.285 2500000002 ALBUTEROL 1.25 MG/3 ML VIAL.NEB 12.336 2500000003 ALBUTEROL 0.63 MG/3 ML VIAL.NEB 8.523 2500000004 ALBUTEROL/IPRATROPIUM 3 ML INH SOL 2.197 2500000005 RACEPINEPHRINE 2.25% 0.5 ML NEB 14.103 2500000006 ALBUTEROL 5 MG/ML 20 ML NEB SOL 80.6415 2500000007 IPRATROPIUM BROMIDE 0.5 MG/2.5 ML NEB 1.517 2500000009 ALBUTEROL 2.5 MG/3 ML VIAL.NEB 1.533 2500000010 ACETYLCYSTEINE-NONFORMULARY 10% 4 ML VIAL 11.8916 2500000011 TIAGABINE HCL 4 MG TAB 31.496 2500000012 ACAMPROSATE-NF 333 MG TABLET.EC 7.592 2500000013 PALIPERIDONE 3 MG TAB.ER.24 87.70887 2500000014 SILDENAFIL-NF 20 MG TAB 7.933 2500000018 LETROZOLE-NF 2.5 MG TAB 0.9 2500000019 BICALUTAMIDE-NF 50 MG TAB 13.44 2500000020 RANOLAZINE 500 MG TAB.ER.12H 34.75906 2500000021 CINACALCET HCL 30 MG TAB 140.674185 2500000022 SODIUM CHLORIDE 1 GM TAB 0.602 2500000023 AZITHROMYCIN 250 MG TAB 14.14 2500000024 LOXAPINE SUCCINATE 25 MG CAP 7.71 2500000025 URSODIOL 300 MG CAP 18.14616 2500000026 BENAZEPRIL 10 MG TAB 0.463 2500000028 ALFUZOSIN-NF 10 MG TAB.ER.24H 3.22 2500000029 SEVELAMER HCL 400 MG TAB 20.46496 2500000030 ANASTROZOLE 1 MG TAB 3.247 2500000031 LOSARTAN POTASSIUM 25 MG TAB 0.357 2500000031 LOSARTAN POTASSIUM 12.5 MG HALFTAB 8.167 2500000032 THEOPHYLLINE 400 MG TAB.ER.24H 8.802 2500000033 SUMAtriptan succinate 100 MG TAB 6.144 2500000034 AMOXICILLIN/POTASSIUM CLAV 875-125 TABLET 4.524 2500000035 MEMANTINE HCL 10 MG TAB 3.833 2500000036 IRBESARTAN-NF 75 MG HALFTAB 0.961 2500000036 IRBESARTAN-NF 150 MG TAB 1.921 2500000037 TRAZODONE HYDROCHLORIDE 25 MG HALFTAB 0.437 2500000037 TRAZODONE HCL 50 MG TAB 0.612 2500000037 TRAZODONE HCL 12.5 MG QUARTERTAB 0.873 2500000038 SACCHAROMYCES BOULARDII 250 MG CAP 5.344 2500000039 MEMANTINE HCL 2.5 MG HALFTAB 1.917 2500000039 MEMANTINE HCL 5 MG TAB 3.833 2500000040 PYRAZINAMIDE 500 MG TAB 12.34916 2500000041 FELODIPINE-NF 5 MG TAB.ER.24H 8.827 2500000043 DILTIAZEM 60 MG TAB 1.612 2500000044 CHLORTHALIDONE 12.5 MG QUARTERTAB 0.268 2500000044 CHLORTHALIDONE 25 MG HALFTAB 0.536 2500000044 CHLORTHALIDONE 50 MG TAB 8.527 2500000045 NADOLOL 10 MG HALFTAB 7.416 2500000045 NADOLOL 20 MG TAB 14.831 2500000047 PHENYTOIN SODIUM EXTENDED 100 MG CAPSULE 4.508 2500000048 LITHIUM CARBONATE 150 MG HALFTAB 1.859 2500000048 LITHIUM CARBONATE 300 MG TAB 1.927 2500000049 FLUDROCORTISONE ACETATE 0.1 MG TAB 6.554 2500000050 DEXAMETHASONE 0.5 MG TAB 0.605 2500000051 ISONIAZID 100 MG TAB 12.443 2500000052 LITHIUM CARBONATE ER 300 MG TABLET.ER 3.142 2500000053 LEVOTHYROXINE SODIUM 12.5 MCG HALFTAB 0.55 2500000053 LEVOTHYROXINE SODIUM 25 MCG TAB 2.605 2500000054 MEGESTROL ACETATE 20 MG HALFTAB 0.934 2500000054 MEGESTROL ACETATE 40 MG TAB 1.942 2500000055 NITROGLYCERIN 0.3 MG TAB.SUBL 5.33 2500000056 NITROGLYCERIN 0.4 MG TAB.SUBL 10.625 2500000057 NITROGLYCERIN 0.6 MG TAB.SUBL 1.78 2500000058 BROMOCRIPTINE MESYLATE 2.5 MG TAB 3.553 2500000059 NIFEdipine 10 MG SGL - LIQUID FILLED CAPSULE 5.055 2500000060 SODIUM BICARBONATE 650 MG TAB 0.134 2500000061 ATENOLOL 12.5 MG HALFTAB 0.373 2500000061 ATENOLOL 25 MG TAB 1.579 2500000062 ENALAPRIL MALEATE 10 MG TAB 4.725 2500000063 hydrALAZINE 10 MG TAB 0.792 2500000064 PERPHENAZINE 8 MG TAB 16.448 2500000065 PRENATAL VITAMIN 1 TABLET 0.277 2500000066 rifAMPin 300 MG CAP 5.25 2500000067 DOCUSATE SODIUM/SENNA 1 TAB 0.323 2500000068 TAMOXIFEN CITRATE 10 MG TAB 3.694 2500000069 ARIPIPRAZOLE 15 MG TAB 12.89 2500000070 ARIPIPRAZOLE 10 MG TAB 14.297 2500000071 FLUOXETINE HCL 20 MG CAP 0.718 2500000072 LISINOPRIL 5 MG TABLET 0.47 2500000073 LISINOPRIL 10 MG TABLET 0.432 2500000074 LISINOPRIL 20 MG TABLET 0.674 2500000075 CLONIDINE TTS-1 PATCH.TDWK 82.695 2500000076 CLONIDINE TTS-2 PATCH.TDWK 121.336875 2500000077 DILTIAZEM S R 60 MG CAP.ER.12H 9.307 2500000078 DILTIAZEM S R 90 MG CAPSULE.SR 16.77596 2500000079 NORTRIPTYLINE 25 MG CAPSULE 1.158 2500000080 CLOZAPINE 12.5 MG HALFTAB 2.002 2500000080 CLOZAPINE 25 MG TAB 4.004 2500000081 NEFAZODONE HCL 50 MG HALFTAB 1.915 2500000081 NEFAZODONE HCL 100 MG TAB 3.83 2500000082 PRAVASTATIN SODIUM 10 MG HALFTAB 1.176 2500000082 PRAVASTATIN SODIUM 20 MG TAB 3.939 2500000083 TORSEMIDE 5 MG QUARTERTAB 0.193 2500000083 TORSEMIDE 10 MG HALFTAB 0.385 2500000083 TORSEMIDE 20 MG TAB 1.129 2500000084 METFORMIN HCL 850 MG TAB 0.739 2500000085 METFORMIN 250 MG HALFTAB 0.767 2500000085 METFORMIN HCL 500 MG TAB 0.776 2500000086 GLIMEPIRIDE 2 MG TAB 0.287 2500000087 CEFPODOXIME PROXETIL 200 MG TAB 31.6324 2500000088 sulfADIAZINE 500 MG TAB - NF 11.97096 2500000089 SUCCIMER 100 MG CAP 44.99607 2500000090 ZAFIRLUKAST 10 MG HALFTAB 2.709 2500000090 ZAFIRLUKAST 20 MG TAB 5.417 2500000091 OLANZAPINE 5 MG TABLET 2.079 2500000093 MIRTAZAPINE 15 MG TAB 1.399 2500000093 MIRTAZAPINE 3.75 MG HALFTAB 5.958 2500000094 LORATADINE 5 MG HALFTAB 1.02 2500000094 LORATADINE 10 MG TABLET 2.045 2500000095 LISINOPRIL 1.25 MG HALFTAB 0.064 2500000095 LISINOPRIL 2.5 MG TAB 0.153 2500000096 PROPAFENONE HCL 225 MG TAB 2.404 2500000097 WARFARIN 0.5 MG HALFTAB 0.17 2500000097 WARFARIN 1 MG TAB 0.339 2500000098 ZINC SULFATE 220 MG CAP 0.375 2500000099 CIPROFLOXACIN 250 MG TAB 2.864 2500000100 CIPROFLOXACIN 500 MG TAB 1.603 2500000101 ASPIRIN 81 MG TABLET.EC 0.395 2500000102 OLANZAPINE 10 MG TAB 3.114 2500000103 DONEPEZIL HCL 10 MG TAB 1.267 2500000104 LOSARTAN POTASSIUM 50 MG TAB 0.303 2500000105 QUINAPRIL HCL 10 MG TAB 0.778 2500000106 VITAMIN B w/ VIT C (RENAL) 1 CAPSULE 3.392 2500000107 MESALAMINE 400 MG TABLET.EC 18.89946 2500000108 BENAZEPRIL 5 MG TAB 0.459 2500000109 OMEPRAZOLE-NF 20 MG CAPSULE.DR 3.488 2500000110 CALCIUM ACETATE 667 MG CAPSULE 2.258 2500000111 ROPINIROLE HCL 0.5 MG TABLET 0.859 2500000112 ROPINIROLE HCL 1 MG TABLET 1.115 2500000113 OXCARBAZEPINE 75 MG HALFTAB 1.097 2500000113 OXCARBAZEPINE 150 MG TAB 1.884 2500000114 rOPINIRole HYDROCHLORIDE 0.25 MG TAB 2.368 2500000115 glipiZIDE XL 5 MG TAB.ER.24 2.839 2500000116 CLOPIDOGREL 75 MG TAB 2.219 2500000117 OLANZAPINE 2.5 MG TAB 1.764 2500000118 AMLODIPINE BESYLATE 2.5 MG TAB 1.362 2500000119 PAROXETINE HCL 10 MG TAB 0.827 2500000119 PAROXETINE HYDROCHLORIDE 5 MG HALFTAB 1.162 2500000120 DEMECLOCYCLINE HCL 150 MG TAB 14.6 2500000121 SITAGLIPTIN 25 MG HALFTAB 34.68306 2500000121 SITAGLIPTIN 50 MG TAB 69.36612 2500000122 TRIHEXYPHENIDYL 2.5 MG HALFTAB 0.43 2500000122 TRIHEXYPHENIDYL HCL 5 MG TAB 6.885 2500000123 IMIPRAMINE HCL 25 MG TAB 2.009 2500000124 VALSARTAN 80 MG TAB 0.942 2500000125 DANTROLENE 25 MG CAP 15.343 2500000126 BUDESONIDE 3 MG CAPDR...ER CAPSULE, DELAYED, AND EXTENDED40.47282 RELEASE 2500000127 VALACYCLOVIR HCL 500 MG TAB 3.77 2500000129 MEXILETINE HCL 200 MG CAP 2.163 2500000130 MELOXICAM 7.5 MG TAB 1.558 2500000131 ENTACAPONE 100 MG HALFTAB 11 2500000131 ENTACAPONE 200 MG TAB 14.28232 2500000132 METHYLDOPA 250 MG TAB 1.582 2500000133 AMITRIPTYLINE HCL 50 MG TABLET 4.023 2500000134 ASPIRIN 325 MG TABLET.DR 0.099 2500000135 SULFAMETHOXAZOLE/TRIMETHOPRIM 800/160 TABLET 1.263 2500000136 ASPIRIN 325 MG TABLET 0.576 2500000138 diphenhydrAMINE HYDROCHLORID 25 MG CAPSULE 0.305 2500000139 PROBENECID 500 MG TAB 4.246 2500000140 DICYCLOMINE HCL 10 MG CAP 0.395 2500000141 BETHANECHOL 12.5 MG HALFTAB 2.075 2500000141 BETHANECHOL CHLORIDE 25 MG TAB 4.287 2500000142 TERBUTALINE SULFATE 5 MG TAB 30.23864 2500000143 TERBUTALINE SULFATE 2.5 MG TAB 24.78512 2500000144 CAPTOPRIL 6.25 MG HALFTAB 0.255 2500000144 CAPTOPRIL 12.5 MG TAB 7.226 2500000145 SUCRALFATE 1 GM TAB 3.58 2500000146 DILTIAZEM 15 MG HALFTAB 0.291 2500000146 DILTIAZEM 30 MG TAB 1.014 2500000147 CLONIDINE HCL 0.1 MG TAB 0.432 2500000148 CLINDAMYCIN HCL 150 MG CAP 2.3 2500000149 BENZTROPINE MESYLATE 0.25 MG HALFTAB 1.493 2500000149 BENZTROPINE MESYLATE 0.5 MG TABLET 2.963 2500000149 BENZTROPINE MESYLATE 1 MG TAB 3.735 2500000150 PREDNISONE 20 MG TABLET 1.863 2500000151 TRAZODONE HCL 100 MG TAB 1.66 2500000152 ACETAZOLAMIDE 250 MG TAB 11.3336 2500000153 PHENYTOIN 50 MG TAB.CHEW 10.786 2500000154 DOCUSATE SODIUM 100 MG CAPSULE 0.267 2500000155 DOXYCYCLINE HYCLATE 100 MG TAB 1.451 2500000156 FERROUS SULFATE 325 MG TABLET.DR 3.583 2500000157 CYCLOBENZAPRINE HCL 2.5 MG HALFTAB 0.196 2500000157 CYCLOBENZAPRINE HCL 10 MG TAB 0.446 2500000158 FOLIC ACID 1 MG TAB 0.662 2500000159 FUROSEMIDE 20 MG TAB 0.611 2500000159 FUROSEMIDE 10 MG HALFTAB 0.649 2500000160 FUROSEMIDE 40 MG TAB 0.415 2500000161 HALOPERIDOL 5 MG TAB 2.143 2500000162 DEXAMETHASONE 2 MG HALFTAB 0.56 2500000162 DEXAMETHASONE 4 MG TAB 1.185 2500000163 hydroCHLOROthiazide 6.25 MG QUARTER TABLET 0.043 2500000163 hydroCHLOROthiazide 25 MG TABLET 0.172 2500000164 hydroCHLOROthiazide
Recommended publications
  • List of New Drugs Approved in India from 1991 to 2000

    List of New Drugs Approved in India from 1991 to 2000

    LIST OF NEW DRUGS APPROVED IN INDIA FROM 1991 TO 2000 S. No Name of Drug Pharmacological action/ Date of Indication Approval 1 Ciprofloxacin 0.3% w/v Eye Indicated in the treatment of February-1991 Drops/Eye Ointment/Ear Drop external ocular infection of the eye. 2 Diclofenac Sodium 1gm Gel March-1991 3 i)Cefaclor Monohydrate Antibiotic- In respiratory April-1991 250mg/500mg Capsule. infections, ENT infection, UT ii)Cefaclor Monohydrate infections, Skin and skin 125mg/5ml & 250mg/5ml structure infections. Suspension. iii)Cefaclor Monohydrate 100mg/ml Drops. iv)Cefaclor 187mg/5ml Suspension (For paediatric use). 4 Sheep Pox Vaccine (For April-1991 Veterinary) 5 Omeprazole 10mg/20mg Short term treatment of April-1991 Enteric Coated Granules duodenal ulcer, gastric ulcer, Capsule reflux oesophagitis, management of Zollinger- Ellison syndrome. 6 i)Nefopam Hydrochloride Non narcotic analgesic- Acute April-1991 30mg Tablet. and chronic pain, including ii)Nefopam Hydrochloride post-operative pain, dental 20mg/ml Injection. pain, musculo-skeletal pain, acute traumatic pain and cancer pain. 7 Buparvaquone 5% w/v Indicated in the treatment of April-1991 Solution for Injection (For bovine theileriosis. Veterinary) 8 i)Kitotifen Fumerate 1mg Anti asthmatic drug- Indicated May-1991 Tablet in prophylactic treatment of ii)Kitotifen Fumerate Syrup bronchial asthma, symptomatic iii)Ketotifen Fumerate Nasal improvement of allergic Drops conditions including rhinitis and conjunctivitis. 9 i)Pefloxacin Mesylate Antibacterial- In the treatment May-1991 Dihydrate 400mg Film Coated of severe infection in adults Tablet caused by sensitive ii)Pefloxacin Mesylate microorganism (gram -ve Dihydrate 400mg/5ml Injection pathogens and staphylococci). iii)Pefloxacin Mesylate Dihydrate 400mg I.V Bottles of 100ml/200ml 10 Ofloxacin 100mg/50ml & Indicated in RTI, UTI, May-1991 200mg/100ml vial Infusion gynaecological infection, skin/soft lesion infection.
  • WHO Drug Information Vol. 12, No. 3, 1998

    WHO Drug Information Vol. 12, No. 3, 1998

    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
  • Fixed Drug Eruption Due to a Cerumenolytic Ear Drop; Hydrogen Peroxide and Boric Acid: a Case Report

    Fixed Drug Eruption Due to a Cerumenolytic Ear Drop; Hydrogen Peroxide and Boric Acid: a Case Report

    ISSN: 2688-8238 DOI: 10.33552/OJOR.2020.04.000577 Online Journal of Otolaryngology and Rhinology Case Report Copyright © All rights are reserved by Akif İşlek Fixed Drug Eruption Due to A Cerumenolytic Ear Drop; Hydrogen Peroxide and Boric Acid: A Case Report Akif İşlek1* and Engin Karaaslan2 1Nusaybin State Hospital, Otolaryngology-Head & Neck Surgery Clinic, Mardin, Turkey 2Nusaybin State Hospital, Dermatology and Venereology, Mardin, Turkey *Corresponding author: Received Date: October 24, 2020 Published Date: November 03, 2020 Akif İşlek, Nusaybin State Hospital, Otolaryngology-Head & Neck Surgery Clinic, Mardin, Turkey. Abstract Treatment of earwax often involves the use of a wax softening agent (cerumenolytic) with or without antimicrobial agents to easily removing. Cerumenolytic agents used to remove and soften earwax areoil-based treatments, water-based treatments. Fixed drug eruption (FDE) is a well- defined, circular, hyperpigmented plaque that usually occurs on the trunk, hands mucosal surfaces, after a systemical application of drugs. In this report, a case with FDE developed after a cerumenolytic agent (hydrogen peroxide and boric acid in water). A definitive diagnosis was made with skin punch biopsy and FDE was treated with oral levocetirizine and topical mometasone. Introduction is a well-defined, circular, hyper pigmenting plaque that usually Cerumen production is a normal and protective process occurs on the genitals, lips, trunk, and hands and the diagnosis for the external ear canal (EAC), but impact of cerumen causes can be confirmed by histopathologic examination of a small punch symptoms such as hearing loss, itching, pain, tinnitus [1]. Cerumen biopsy specimen [5]. In this report, a case with FDE developed after impaction is defined as an accumulation of cerumen in the a cerumenolytic agent (hydrogen peroxide and boric acid in water) external ear [2].
  • United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar

    United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar

    USOO896.9514B2 (12) United States Patent (10) Patent No.: US 8,969,514 B2 Shailubhai (45) Date of Patent: Mar. 3, 2015 (54) AGONISTS OF GUANYLATECYCLASE 5,879.656 A 3, 1999 Waldman USEFUL FOR THE TREATMENT OF 36; A 6. 3: Watts tal HYPERCHOLESTEROLEMIA, 6,060,037- W - A 5, 2000 Waldmlegand et al. ATHEROSCLEROSIS, CORONARY HEART 6,235,782 B1 5/2001 NEW et al. DISEASE, GALLSTONE, OBESITY AND 7,041,786 B2 * 5/2006 Shailubhai et al. ........... 530.317 OTHER CARDOVASCULAR DISEASES 2002fOO78683 A1 6/2002 Katayama et al. 2002/O12817.6 A1 9/2002 Forssmann et al. (75) Inventor: Kunwar Shailubhai, Audubon, PA (US) 2003,2002/0143015 OO73628 A1 10/20024, 2003 ShaubhaiFryburg et al. 2005, OO16244 A1 1/2005 H 11 (73) Assignee: Synergy Pharmaceuticals, Inc., New 2005, OO32684 A1 2/2005 Syer York, NY (US) 2005/0267.197 A1 12/2005 Berlin 2006, OO86653 A1 4, 2006 St. Germain (*) Notice: Subject to any disclaimer, the term of this 299;s: A. 299; NS et al. patent is extended or adjusted under 35 2008/0137318 A1 6/2008 Rangarajetal.O U.S.C. 154(b) by 742 days. 2008. O151257 A1 6/2008 Yasuda et al. 2012/O196797 A1 8, 2012 Currie et al. (21) Appl. No.: 12/630,654 FOREIGN PATENT DOCUMENTS (22) Filed: Dec. 3, 2009 DE 19744O27 4f1999 (65) Prior Publication Data WO WO-8805306 T 1988 WO WO99,26567 A1 6, 1999 US 2010/O152118A1 Jun. 17, 2010 WO WO-0 125266 A1 4, 2001 WO WO-02062369 A2 8, 2002 Related U.S.
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0158930 A1 Hirata Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2011/0158930 A1 Hirata Et Al

    US 2011 O15893 OA1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0158930 A1 Hirata et al. (43) Pub. Date: Jun. 30, 2011 (54) METHOD FOR TREATMENT OF RRTABLE Related U.S. Application Data BOWEL, SYNDROME (60) Provisional application No. 61/190.559, filed on Aug. 28, 2008. (75) Inventors: Takuya Hirata, Tokyo (JP); Toshiyuki Funatsu, Tokyo (JP); Publication Classification Yoshihiro Keto, Tokyo (JP); (51) Int. Cl. Shinobu Akuzawa, Tokyo (JP) A63L/78 (2006.01) C07D 403/06 (2006.01) (73) Assignee: ASTELLAS PHARMA INC., A6IPI/00 (2006.01) Tokyo (JP) A6IPL/T2 (2006.01) (52) U.S. Cl. ................................... 424/78.01: 548/302.7 (21) Appl. No.: 13/061,384 (57) ABSTRACT A method for treatment of a patient suffering from irritable (22) PCT Fled: Aug. 27, 2009 bowel syndrome with diarrhea or mixed irritable bowel syn drome, which comprises administering to the patient a thera (86) PCT NO.: PCT/UP2009/064904 peutically effective amount of ramosetron or a pharmaceuti cally acceptable salt thereof in combination with a S371 (c)(1), therapeutically effective amount of polycarbophil or a phar (2), (4) Date: Feb. 28, 2011 maceutically acceptable salt thereof. Patent Application Publication Jun. 30, 2011 Sheet 1 of 2 US 2011/O1589.30 A1 Fig.1 s 120 aw *e 100 aS$ 100 80 isd 80 v s 60 se sk sk 60 40 6 40 se g 20 20 - a k es O -- - - - , , , g- O W 0. 0.3 1 100 300 000 0.3 g/kg 300 mg/kg 0.3 g/kg + s S.
  • Common Ear, Nose & Throat Problems

    Common Ear, Nose & Throat Problems

    Common Ear, Nose & Throat Problems The information provided in this presentation is not intended to guide treatment or aid in making a diagnosis. Always consult a physician or nurse practitioner. Copyright 2002, 2014, Kevin T. Kavanagh All Rights Reserved www.entusa.com Normal Larynx Normal larynx in a 44 yr old non-smoker Go to http://www.entusa.com/normal_larynx.htm to View Video Copyright 2002, 2014, Kevin T. Kavanagh All Rights Reserved www.entusa.com Acute Laryngitis This video shows the function of the larynx in a 24 yr old patient with acute laryngitis. Talking was painful and she only talked in a faint whisper. Go to http://www.entusa.com/laryngitis.htm to View Video Copyright 2002, 2014, Kevin T. Kavanagh All Rights Reserved www.entusa.com Vocal Cord Paralysis This video shows the function of a larynx with a paralyzed left true vocal cord. The patient has lung cancer. She has a poorly compensated breathy voice which is difficult to understand. This patient had a 55 pack year history of smoking. Go to http://www.entusa.com/vocal_cord_paralysis_2.htm to View Video Copyright 2002, 2014, Kevin T. Kavanagh All Rights Reserved www.entusa.com Vocal Cord Polyp This video shows the function of a larynx with a vocal cord polyp on the right true vocal cord. This patient smoked one pack a day for 30 years. Go to http://www.entusa.com/larynx_polyp-9.htm to View Video Copyright 2002, 2014, Kevin T. Kavanagh All Rights Reserved www.entusa.com Laryngeal Cancer This video shows the function of a larynx with a large T1b Cancer on both true vocal cords and anterior commissure in 72 yr old male with a 150 pack year history of smoking.
  • EAR, NOSE and OROPHARYNX Updated: October 2020

    EAR, NOSE and OROPHARYNX Updated: October 2020

    Derbyshire Medicines Management, Prescribing and Guidelines DERBYSHIRE PRIMARY CARE FORMULARY CHAPTER 12: EAR, NOSE AND OROPHARYNX Updated: October 2020 The following prescribing guidelines are relevant to the ENT chapter and can be found here: • Allergic Rhinitis in adults and adolescents over 12 years of age • Management of chronic rhinosinusitis with or without nasal polyps 12.1 DRUGS ACTING ON THE EAR 12.1.1 Otitis externa Investigation is not routinely recommended for the initial diagnosis of otitis externa. Group Drug Astringent/acidic Acetic acid 2% ear spray preparations Self-care: patients are advised to purchase this over the counter Gentamicin 0.3% ear/eye drops* Antibiotic preparations Ciprofloxacin 2mg/ml ear drops 0.25ml unit dose PF Betnesol-N ear/eye/ nose drops* Combined corticosteroid (Betamethasone 0.1% & neomycin 0.5%) and aminoglycoside Otomize ear spray* antibiotic preparations (Dexamethasone 0.1%, neomycin 0.5% & acetic acid 2%) Corticosteroid Prednisolone 0.5% ear/eye drops Lower potency preparations Betamethasone 0.1% ear/eye/ nose drops Higher potency Antifungal preparations Clotrimazole 1% solution 20ml (with dropper) * In view of reports of ototoxicity, manufacturers contra-indicate treatment with topical aminoglycosides in patients with a perforated tympanic membrane (eardrum) or patent grommet. 1. The following are GREY, not for first line empirical use, and should only be used when sensitivity is confirmed through swab results- • Hydrocortisone acetate 1%/gentamicin 0.3% ear drops • Flumetasone pivalate 0.02%/clioquinol 1% ear drops 2. How should I treat acute diffuse otitis externa? (CKS) • Remove or treat any precipitating or aggravating factors. • Prescribe or recommend a simple analgesic for symptomatic relief.
  • 10/15-Hour Medication Test Answers

    10/15-Hour Medication Test Answers

    Appendix 10/15-Hour Medication Test Answers Name _________________________________ Facility _________________________________ Part 1: Match the term or phrase on the right with the abbreviation or term on the left by placing the correct letter on the appropriate line. _____ 1. PRN (p) a. milligram _____ 2. ac (e) b. at bedtime _____ 3. stat (j) c. Medication Administration Record _____ 4. SL (k) d. over the counter _____ 5. MAR (c) e. before meals _____ 6. mg (a) f. tablespoonful _____ 7. pc (m) g. placed and affixed to the skin _____ 8. OTC (d) h. teaspoonful _____ 9. Subcutaneous (r) i. milliliter _____ 10. po (n) j. immediately _____ 11. qhs (b) k. sublingual _____ 12. tbsp (f) l. placed under the tongue _____ 13. transdermal (g) m. after meals _____ 14. ml (i) n. by mouth _____ 15. gm (o) o. gram _____ 16. QOD (q) p. as needed _____ 17. tsp (h) q. every other day _____ 18. sublingual (l) r. inject into the fat with a syringe Medication Administration – March 2021 10/15-Hour Training Course for Adult Care Homes 4 Appendix 10/15-Hour Medication Test Answers – Continued Part 2: Fill in the blank with the appropriate word or term. You may choose to use the word bank below. 19. A heart tablet taken by mouth and swallowed is an example of a medication taken by the oral route. 20. A medication that is inserted into the rectum is given using the rectal route. 21. A topical medication is applied directly to the skin surface.
  • GENTAMICIN Eye/Ear Drops 0.3% W/V Gentamicin Sulphate Please

    GENTAMICIN Eye/Ear Drops 0.3% W/V Gentamicin Sulphate Please

    GENTAMICIN Eye/Ear Drops 0.3% w/v Gentamicin Sulphate Please read this leaflet carefully before you start using this medicine. Keep this leaflet. You may need to read it again. If you have further questions, please ask your doctor or pharmacist. This medicine has been prescribed for you personally and you should not pass it on to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. The medicine will be called Gentamicin in this leaflet. In this leaflet: 1. What Gentamicin is and what it is used for 2. Before you use Gentamicin 3. How to use Gentamicin 4. Possible side effects 5. How to store Gentamicin 6. Further information 1. WHAT GENTAMICIN IS AND WHAT IT IS USED FOR Gentamicin eye/ear Drops are a sterile, preserved, aqueous solution used as eye/ear drops. The active ingredient Gentamicin is an antibiotic used to kill bacteria which cause infection. It is used for the management of eye & ear infection. 2. BEFORE YOU USE GENTAMICIN Do not use if you are allergic to Gentamicin, any of the ingredients, or any other aminoglycoside antibiotics if you have a perforated ear drum if you suffer from myasthenia gravis and related conditions Before you use Gentamicin: Take special care with Gentamicin Avoid prolonged use The drops must not be used in the ear if the ear drum is damaged in any way.
  • Therapeutic Class Overview Otic Fluoroquinolones

    Therapeutic Class Overview Otic Fluoroquinolones

    Therapeutic Class Overview Otic Fluoroquinolones Therapeutic Class • Overview/Summary: This review will focus on the otic fluoroquinolone antibiotics.1-4 Topical corticosteroids help to aid in the resolution of the inflammatory response accompanying bacterial infections.3,4 Fluoroquinolones are broad-spectrum antimicrobial agents that directly inhibit bacterial deoxyribonucleic acid (DNA) synthesis by blocking the actions of DNA gyrase and topoisomerase IV, which leads to bacterial cell death.5 The otic antibacterials are approved for the treatment of otitis externa and otitis media. Otitis externa (also known as swimmer’s ear) is an inflammatory condition of the external ear canal auditory canal or auricle, usually from infection. Common infectious pathogens include S. aureus, S. epidermidis and P. aeruginosa; however, several other gram-positive, gram-negative and anaerobic infections along with polymicrobic infections occur frequently.6 Topical antibacterials (alone or in combination with a corticosteroid) are very effective and systemic therapy is generally not required.7 Acute otitis media is an inflammatory condition of the middle ear with middle ear effusion and symptoms include otalgia, hearing loss and vertigo.8 Common pathogens in children include S. pneumoniae and H. influenzae (and M. catarrhalis in children).8,9 Oral antibacterials are generally the initial treatment option for children and adults; however, topical antibacterials with or without corticosteroids may be used in patients with perforated tympanic membranes, tympanostomy
  • Standard Treatment Guidelines and Essential Drugs List

    Standard Treatment Guidelines and Essential Drugs List

    STANDARD TREATMENT GUIDELINES AND ESSENTIAL DRUGS LIST FOR THE MINISTRY OF HEALTH, TONGA- 2007. Standard Treatment Guidelines Tonga 2007 Standard Treatment Guidelines and Essential Drugs List: Ministry of Health. First Edition, 2007 Copyright © 2007, Ministry of Health, Tonga All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, scanned or transmitted in any form without the permission of the copyright owner. Ministry of Health PO Box 59 Nuku’alofa Tonga Phone: 676 23200 Fax: 676 24291 E-mail address: [email protected] Editors: Siale ‘Akau’ola & Siutaka Siua Cover design by: Owen Towle Formatted by: T. Nauna Paongo Printed by: Taulua Press STG 2 Ministry of Health Standard Treatment Guidelines Tonga 2007 TABLE OF CONTENTS 1. FOREWORD: 13 2. ABBREVIATIONS AND ACRONYMS: 14 3. ACKNOWLEDGEMENTS: 17 4. INTRODUCTION: 19 5. ACCIDENT AND EMERGENCY (A&E): 21 5.1. General Approach to A&E 21 5.2. Cardiac Arrest 26 5.3. Other Life Threatening Emergencies 30 5.4. Infectious Diseases 52 5.5. Severe Hypertension 58 5.6. Abdominal Pain 59 5.7. Surgical Problems 60 5.8. Red Eye 66 5.9. Dog Bite 67 6. CARDIOVASCULAR CONDITIONS. 68 6.1. Heart Failure 68 6.2. Myocardial Infarction 72 6.3. Cardiogenic Shock 77 6.4. Acute Coronary Syndrome (ACS) 79 6.5. Cardiac Arrythmias 80 6.6. Cardiac Arrest 87 6.7. Hypertension 89 6.8. Aortic Dissection 93 6.9. Bacterial Endocarditis 96 6.10. Infective Endocarditis Prophylaxis 97 7. CENTRAL NERVOUS SYSTEM (CNS) CONDITIONS 104 7.1 Headache 104 STG 3 Ministry of Health Standard Treatment Guidelines Tonga 2007 7.2 Seizures 107 7.3 Meningitis 108 7.4 Stroke 108 7.5 Involuntary Movement Disorders 110 7.6 Epilepsy 111 8 COMMON EAR, NOSE AND THROAT PROBLEMS.
  • Texas Medication Aides Basic Course Curriculum for Nursing Facilities and Related Institutions

    Texas Medication Aides Basic Course Curriculum for Nursing Facilities and Related Institutions

    Texas Medication Aides Basic course curriculum for Nursing Facilities and related institutions Effective Date: January 2017 Texas Health and Human Services Commisson (HHSC) Medication Aide Program, E‐416 P.O. Box 14930, Austin, Texas 78714‐9030 Communicate before you medicate! Helping people make the best of medications REVISED JUNE 2016 | Texas Health and Human Services Commisson (HHSC) HHSC Licensing and Credentialing TEXAS MEDICATION AIDE AND BASIC COURSE CURRICULUM 100‐hour curriculum Acknowledgements We would like to extend a very special thank you to the following people who worked many hours in revising and updating this curriculum. Your cooperation and dedication is appreciated. Darren Christian, R.N., Texas Health and Human Services Commisson, Elizabeth Demps, Texas Health and Human Services Commisson, Katherine Hafner, B.S, R.Ph, Fellow in the American Society of Consultant Pharmacists, Kim Lammons Texas Health and Human Services Commisson, Debi Majo, BSN R.N., TMF Health Quality Institute, Elizabeth McManamy, R.Ph, Texas Health and Human Services Commisson, Joyce Meredith, Texas Health and Human Services Commisson, Carolyn Reese, MSN, R.N., Blinn College, Brenda Renfro‐King, R.N., McLennan Community College, Jacqueline Smith, Texas Health and Human Services Commisson, Camden Frost, Texas Health and Human Services Commisson, Sean Steele, Texas Department on Aging and Disability Services, Sunny Stout, R.N., Senior Care Centers, Mavon Tidwell, R.N., Marble Falls High School, Kingsland Hills Care Center, Anne Trejo, Texas Health and Human Services Commisson. © 2016 Texas Health and Human Services Commisson (formerly Texas Department of Human Services) TEXAS HEALTH AND HUMAN SERVICES COMMISSION (HHSC) 1 TEXAS MEDICATION AIDE AND BASIC COURSE CURRICULUM 100‐hour curriculum Table of Contents: Medication Aide and basic course curriculum Unit I.